NIAID/GSK Ebola Vaccine
NIAID/GSK Ebola Vaccine Overview
NIAID/GSK Ebola vaccine is an experimental vaccine being tested by the National Institute of Allergy and Infectious Diseases (NIAID) in a phase I clinical trial designed to test for safety and the ability to generate an immune response.
NIAID will test two versions of the NIAID/GSK vaccine: a bivalent version containing genetic material derived from the Zaire and Sudan Ebola species and a monovalent version derived from genetic material from only the Zaire Ebola species.
The Ebola genetic material contained in the investigational vaccine cannot cause someone to become infected with Ebola.
The initial safety and immunogenicity data from the Phase 1 NIAID/GSK Ebola vaccine trials are expected by late 2014.